Viral shedding after p53 adenoviral gene therapy in 10 cases of esophageal cancer

Cancer Science

Volumn 101, Issue 1, 2010, Pages 289-291

  Kawahira, Hiroshi ^a   Matsushita, Kazuyuki ^a   Shiratori, Tooru ^a   Shimizu, Takanori ^a   Nabeya, Yoshihiro ^a   Hayashi, Hideki ^a,b   Ochiai, Takenori ^a   Matsubara, Hisahiro ^a   Shimada, Hideaki ^a,c  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P53; VIRUS DNA;

ARTICLE; CANCER GENE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; ESOPHAGUS CANCER; FECES ANALYSIS; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALIVA ANALYSIS; URINALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRUS SHEDDING;

ADENOVIRIDAE; ESOPHAGEAL NEOPLASMS; GENE THERAPY; GENES, P53; HUMANS; POLYMERASE CHAIN REACTION; VIRUS SHEDDING;

EID: 71849100673     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01381.x     Document Type: Article

References (13)

1. Wang Y, Yang Z, Liu S. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer 2005, 92(8):1414-20.
2. Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 2004, 11(Suppl 1):S98-S108.
3. Swisher SG, Roth JA, Nemunaitis J. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91(9):763-71.
4. Fujiwara T, Tanaka N, Kanazawa S. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006, 24(11):1689-99.
5. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007, 9(10):910-21.
6. Shimada H, Matsubara H, Shiratori T. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006, 97(6):554-61.
7. Dummer R, Bergh J, Karlsson Y. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 2000, 7(7):1069-76.
8. Sauthoff H, Hu J, Maca C. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003, 14(5):425-33.
9. Nemunaitis J, Khuri F, Ganly I. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001, 19(2):289-98.
10. DeWeese TL, van der Poel H, Li S. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 61(20):7464-72.
11. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 1997, 26(2-3):71-90.
12. Griscelli F, Opolon P, Saulnier P. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003, 10(5):386-95.
13. Lin X, Huang H, Li S. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007, 6(5):648-53.